Back to search
Moderate to Severe Genital Psoriasis
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Moderate to Severe Genital Psoriasis trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Moderate to Severe Genital Psoriasis trials you may qualify forPhase 3 study to evaluate the efficacy and safety of subcutaneous tildrakizumab in subjects with moderate to severe genital psoriasis.
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe…
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic tre…
This Phase 3 multicenter, randomized, placebo-controlled, double-blind study is designed to evaluate the efficacy and safety of apremilast in subjects with mode…
The main purpose of this study is to evaluate the efficacy and safety of the study drug ixekizumab compared to placebo in participants with moderate-to-severe g…